UK Primary Immunodeficiency Network change in advice for children (under 18 years) during COVID-19

Gary Hodgson, Medicines Information Pharmacist, North West Medicines Information CentrePublished Last updated See all updates

Summary of the change in advice for children with Primary Immunodeficiency in the context of COVID-19.

Background

The UK Primary Immunodeficiency Network (UKPIN) provides advice on the risk of COVID-19 in children particularly those with primary immunodeficiency.

The majority of children with primary immunodeficiency are not considered at increased risk of severe COVID-19 disease and should be treated exactly the same as other children. This includes continuing to go to school.

Those patients under 18 years of age (who do not have an extremely vulnerable diagnosis) that are on: immunoglobulin replacement therapy, prophylactic antibiotics or immunosuppressive medication including biologics / monoclonal antibodies are not considered at high risk of COVID-19 disease.

A small group of children with the most severe forms of primary immunodeficiency remain at high risk of COVID-19 disease (as well as being vulnerable to other common viral infections). These patients remain in the extremely vulnerable group.

Change history

  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Resources checked and information remains correct.
  1. Published